Pfizer (PFE) Non-Current Assets (2016 - 2025)
Pfizer (PFE) has disclosed Non-Current Assets for 17 consecutive years, with $3.3 billion as the latest value for Q4 2025.
- Quarterly Non-Current Assets rose 2.3% to $3.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 billion through Dec 2025, up 2.3% year-over-year, with the annual reading at $3.3 billion for FY2025, 2.3% up from the prior year.
- Non-Current Assets for Q4 2025 was $3.3 billion at Pfizer, down from $161.8 billion in the prior quarter.
- The five-year high for Non-Current Assets was $178.7 billion in Q1 2024, with the low at $3.0 billion in Q4 2023.
- Average Non-Current Assets over 5 years is $102.1 billion, with a median of $128.6 billion recorded in 2022.
- The sharpest move saw Non-Current Assets decreased 15.41% in 2022, then skyrocketed 300.49% in 2023.
- Over 5 years, Non-Current Assets stood at $3.6 billion in 2021, then fell by 15.41% to $3.0 billion in 2022, then fell by 0.17% to $3.0 billion in 2023, then increased by 7.11% to $3.2 billion in 2024, then rose by 2.3% to $3.3 billion in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods came in at $3.3 billion, $161.8 billion, and $162.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.